Plain-English translation of NCT07733089 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to treat plaque psoriasis. About half of participants will receive the medication at different dose schedules over 8 weeks, while the other half will receive a placebo (a dummy pill with no active ingredient). Researchers want to see how safe the treatment is, whether people can tolerate it well, and whether it actually helps reduce psoriasis symptoms.
Plaque psoriasis can be difficult to manage and current treatments don't work well for everyone. This trial is exploring whether this medication could offer patients a new, effective option with fewer side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or a placebo for 8 weeks. You'll take your assigned treatment on a specific schedule and attend clinic visits so researchers can check your psoriasis, take blood samples, and monitor how you're feeling. Throughout the study, you'll need to avoid other psoriasis treatments and light therapies so that researchers can clearly see how the medication affects your skin.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Netherlands